Study Of Anti-IGF-IR CP-751,871 In Patients With Solid Tumors

Sarcoma, Ewing's Clinical Trial

Official title:
Phase 1, Open Label, Multiple Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of CP 751,871 In Patients With Advanced Solid Tumors

Status Completed

Clinical Trial Summary

This is a phase 1 study of anti-IGF-IR CP-751,871 in patients with solid tumors currently enrolling patients 9 years old and older with Ewing's sarcoma family of tumors (Ewing's, PNET and Askin's).

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00474760
Study type	Interventional
Source	Pfizer
Contact
Status	Completed
Phase	Phase 1
Start date	August 2005
Completion date	October 2012

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00520936` - A Study of Pemetrexed in Children With Recurrent Cancer	Phase 2
Completed	`NCT00001209` - A Pilot Study for the Treatment of Patients With Metastatic and High Risk Sarcomas and Primitive Neuroectodermal Tumors	Phase 1
Completed	`NCT00464620` - Trial of Dasatinib in Advanced Sarcomas	Phase 2
Completed	`NCT00824083` - Functional and Clinical Long-Term Outcome of Ewing Sarcoma Treatment	N/A
Active, not recruiting	`NCT00186992` - Radiation Therapy to Treat Musculoskeletal Tumors	Phase 2
Terminated	`NCT00617890` - A Study to Determine the Activity of Robatumumab (SCH 717454) in Participants With Relapsed Osteosarcoma or Ewing's Sarcoma (MK-7454-002/P04720)	Phase 2
Completed	`NCT01962103` - Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors	Phase 1/Phase 2